ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. Source
No articles found.
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
Stericycle is a multinational business-to-business services company with a core pu...
Stericycle is a multinational business-to-busin...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a company based in Cedar Knolls, NJ was...
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a co...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Join the National Investor Network and get the latest information with your interests in mind.